Sanofi Receives FDA Approval to Market Diabetes Treatment Soliqua

By Inti Landauro

PARIS--Sanofi SA (SAN.FR) Tuesday said the U.S. Food and Drug Administration has approved the sale of Soliqua, a new diabetes treatment.

The authorization from the FDA will allow Sanofi to market the new treatment in the U.S., and is part of the company's efforts to offset an expected decline in revenue following the loss of patent protection for its Lantus insulin treatment.

Soliqua is a combination of two drugs already on the market, including Lantus. Sanofi says a single daily dose of the mix will allow a patient to improve the control of glycemia level.

The FDA is the first regulator to approve the sale of Soliqua.

The Paris-based company is one of the world's biggest makers of diabetes drugs, though that part of the business is under pressure from increasingly cost-conscious heath-care systems. The company expects revenue from diabetes drugs to decline as competition between insulin makers intensifies.

Write to Inti Landauro at [e-mail]

(END) Dow Jones Newswires

November 22, 2016 03:29 ET (08:29 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.